The popularity of Viagra initially fueled a surge for pharma, but recent shifts present a murky scenario for investors. Off-patent alternatives are eroding revenue, and continued patent challenges add additional risk https://keithjtnv400559.educationalimpactblog.com/62722134/sildenafil-and-big-pharma-a-precarious-investment